Lv1
18 积分 2026-03-17 加入
Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study
3天前
已完结
Assessing the performance of methods for central statistical monitoring of a binary or continuous outcome in multi-center trials: A simulation study
17天前
已完结
Evaluation of current statistical methods for implementing Quality Tolerance Limits
23天前
已完结
FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer
26天前
已完结
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
2个月前
已完结
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial
2个月前
已完结
Robust meta‐analytic‐predictive priors in clinical trials with historical control information
2个月前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
3个月前
已完结
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
3个月前
已完结
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial
3个月前
已完结
皖公网安备34019202002308
